Drug trial aims to shield unborn babies from dangerous blood condition
Prevention
Terminated
This study tested an investigational drug called RLYB212, given to pregnant women at higher risk of developing an immune response that can harm their baby's platelets. The main goals were to check the drug's safety and how it moves through the body in both the mother and baby. Th…
Phase: PHASE2 • Sponsor: Rallybio • Aim: Prevention
Last updated Apr 01, 2026 14:42 UTC